Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the RSV L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection

Clicks: 1
ID: 317272
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #500 of 530 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 530 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: S-337395 is a novel inhibitor of the respiratory syncytial virus (RSV) L-protein, and a potential oral antiviral against RSV. This phase 2a, randomized, double-blind, placebo-controlled, single-center, proof-of-concept trial conducted in the United Kingdom (April-October 2024) evaluated the efficacy, safety, and dose-response relationship of S-337395 against RSV infection in a human challenge model. METHODS: Healthy adults aged 18-55 years meeting predefined eligibility criteria were inoculated with RSV-A Memphis 37b on Day 0. Nasal washes were collected for quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) assessment twice daily on Days 2-12 and once on Day 13. Participants were randomized 5:13:13:13:13 to receive S-337395 (1, 10, 30, or 300 mg) or placebo, once daily for 5 days upon evidence of infection. Efficacy analyses were conducted in participants with confirmed RSV infection in intent-to-treat infected (ITT-I) set. Safety was assessed in all randomized participants. Dose-response was evaluated across a wide dose range (1-300 mg). RESULTS: Of 114 randomized participants, 60 comprised the ITT-I set. Covariate-adjusted mean viral load area under the curve (VL-AUC) was significantly lower in the 30-mg and 300-mg groups by qRT-PCR (64.87% and 88.94% reductions, respectively, both p<0.05) and by viral culture assay (72.32% and 86.17% reductions, respectively, both p<0.05). Total Symptom Score AUC was 78.15% lower in the 300-mg group (p<0.05). S-337395 was well-tolerated without any safety concerns. CONCLUSIONS: S-337395 significantly reduced viral load, viral titer, and symptoms, and was well-tolerated in this human challenge study.
Reference Key
openalex_W7164858346 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Stuart Byrne, Takamichi Baba, Nao Kawaguchi, Atsuko Yamamoto, Yoshiyuki Nakano, Caroline Dorrepaal, Brandon Löndt, Alex Mann, Nikolay Veselinski, Takeki Uehara
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag367
URL
https://doi.org/10.1093/cid/ciag367
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.